Bausch Health Value Stock - Dividend - Research Selection
Bausch Health Companies Inc.
ISIN: CA0717341071, WKN: A2JQ1X
Market price: 27,61 USD
Bausch Health Companies Inc. Fundamental data and company key figures of the share
| Annual reports in USD | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | 02-03-2021 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | 1.111.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | -302.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | 809.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | 535.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | 31.199.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | -560.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | -1,576 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | 355.422.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | 8.027.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | BHC |
| Market Capitalization | 9.813.201.920,00 USD |
| Country | |
| Indices | S&P/TSX 60 |
| Sectors | |
| Raw Data Source | US GAAP in Millionen USD |
| Stock Split | 2000-10-16,2.0000/1.0000; 2000-10-05,2.000000/1.000000; 2000-01-20,2.0000/1.0000; 1996-01-17,3.0000/1.0000 |
| Internet | www.valeant.com |
Description of the company
Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.